Managing Dyskinesia Amid Advancements in Parkinson Disease Therapies
Daniel Kremens, MD, JD; and Robert Hauser, MD, MBA, discuss how recent advancements in Parkinson disease therapies, including new extended-release formulations and subcutaneous pumps, may impact dyskinesia management, while exploring treatment strategies for patients with troublesome dyskinesia through clinical case examples.
EP. 1: Recent Advancements in Parkinson Disease Treatment Options
July 14th 2025Panelists discuss how recent advancements in Parkinson disease treatment include 3 newly approved medications—an oral extended-release carbidopa-levodopa with mucoadhesive properties, a subcutaneous foslevodopa infusion, and a subcutaneous apomorphine infusion—that aim to provide more continuous dopamine stimulation and reduce motor fluctuations by offering longer-lasting benefits and smoother symptom control compared with traditional immediate-release formulations.
EP. 2: Impact of Newer Therapies on Dyskinesia in Parkinson Disease
July 14th 2025Panelists discuss how newer Parkinson disease therapies may impact dyskinesia management by potentially providing continuous dopaminergic stimulation that could prevent dyskinesia development if used early, though current evidence from phase 3 trials shows mixed results with improvements in "good on time" (on time without troublesome dyskinesia) but limited reduction in existing troublesome dyskinesia, suggesting that while these treatments offer promise, more research is needed to determine their effectiveness in reducing dyskinesia in patients who already experience it.
